Left Pulmonary Artery Aneurysm: A Post-stenotic Pulmonary ...

Hypertension: How Frequently Should You Monitor Your Blood Pressure?

Why Do Your Blood Pressure Numbers Hold The Key To Your Well-Being?

Hypertension, commonly known as high blood pressure, has gained quite a notorious reputation among healthcare professionals. Why? Well, it's a master of disguise, operating in stealth mode. Unlike other conditions with noticeable warning signs, hypertension often shows no symptoms until it spirals out of control.

Here's An Eye-Opening Fact

Did you know that 1 in 5 people with hypertension are unaware of their condition? Surprising, No? So, what's the solution? Once you reach the age of 40, it becomes mandatory to keep a close eye on your blood pressure for any signs of hypertension. Don't let hypertension catch you off guard stay informed, monitor regularly and ensure a healthier future for all.

How Frequently Should You Monitor Your Blood Pressure?

After that, it's OK to check it once to twice weekly. Invest in a remote personal health monitor that can help you easily track your blood pressure. H360 can be one such investment towards health. A single device that can help you reap the benefits of multiple body vitals, including blood pressure, complete 12-lead ECG, heart rate monitoring & SPO2. One can quickly gauge their blood pressure through the device by placing a finger on the sensor.

When To Be Alarmed?

Essential Hypertension, also known as primary hypertension, occurs when an underlying medical condition does not cause high blood pressure. Secondary Hypertension is an underlying condition or disease, such as obstructive sleep apnea, kidney injury, adrenal disease, hyperparathyroidism, pre-existing thyroid conditions, coarctation (constriction or tightening) of the aorta, or specific medication side effects.

Can The Age And Gender Of A Person Be A Driving Factor In Hypertension?

Age is an independent factor in determining if the person has Hypertension. However, the gap between genders begins to close. Lifestyle factors, genetics, underlying medical conditions, and other variables also contribute to the development and management of hypertension. Regular blood pressure monitoring with a personal health monitor can help assess individual risk factors. Start managing your heart health today and share the data easily with your Health Provider in just a touch.

Adverse Effects Of High Blood Pressure

Many people are unaware that persistent hypertension can lead to Stroke or Cardiac Death, Ischemic heart disease, Heart Failure and Left ventricular hypertrophy (excessive thickening of the heart muscle), Kidney Damage, Vision Problems and Hypertensive Crisis that may require Hospitalization.

How Can Hypertension Be Managed?

Start Regular Monitoring and take charge of your Heart Health now! Buy a device that helps you screen your heart in seconds by grabbing a 12-Lead ECG without connecting wires or leads.

Total Wellness is now just a click away.

Follow us on

Don't Miss Out on the Latest Updates.Subscribe to Our Newsletter Today!

Subscribe Now

Zilebesiran Shows Early Promise For Treating Hypertension

Zilebesiran, an investigational RNA interference therapeutic agent, shows early promise as a hypertension treatment.

The medication reduces the production of angiotensinogen, Akshay S. Desai, MD, MPH, of Brigham and Women's Hospital in Boston, Massachusetts, and colleagues explained in the New England Journal of Medicine. The drug strongly binds to the hepatic asialoglycoprotein receptor, thereby reducing angiotensinogen messenger RNA levels and angiotensinogen translation.

In a phase 1 study (ClinicalTrials.Gov number, NCT03934307), 107 patients (aged 18 to 65 years) with stage 1 to 2 hypertension and minimal comorbidities received a single subcutaneous dose of zilebesiran (10, 25, 50, 100, 200, 400, or 800 mg) or placebo. At baseline, mean seated systolic blood pressure was 130 to 165 mm Hg.

Serum angiotensinogen levels decreased as the administered dose of zilebesiran increased (r= −0.56 at week 8), the investigators reported. At week 8, single doses of zilebesiran of 200mg or more were associated with decreases in systolic blood pressure of more than 10 mm Hg and diastolic blood pressure of more than 5 mm Hg. These blood pressure changes were sustained throughout the day and overnight and continued until week 24.

Other results from the study showed that blood pressure-lowering was greater when zilebesiran was taken along with irbesartan. A high-salt diet (5.75g per day) reversed the blood pressure-lowering effect of zilebesiran.

The study's primary end point was the frequency of adverse events. Adverse events reported in at least 5% of patients were headache, injection-site reaction, and upper respiratory tract infection. No one experienced hypotension, hyperkalemia, worsening of kidney function, hospitalization, or death.

Patients with secondary hypertension, diabetes, stage 3 or higher chronic kidney disease, or a history of cardiovascular events were excluded from the trial.

"Overall, these preliminary data regarding efficacy and safety support the potential for further study of quarterly or twice-yearly administration of zilebesiran as a treatment for patients with hypertension," according to Dr Desai's team. The phase 2 KARDIA-1 study is underway (ClinicalTrials.Gov number, NCT04936035). The KARDIA-2 study (NCT05103332) is investigating zilebesiran as add-on antihypertensive treatment.

In an accompanying editorial, Rhian M. Touyz, MB, BCh, PhD, of McGill University Health Centre in Montreal, Canada, discussed zilebesiran in the context of current antihypertensive therapies and other investigational therapies.

"Angiotensinogen suppression in the liver by [a small interfering RNA] is a novel and exciting means of targeting the renin-angiotensin system: it offers specificity, long-term efficacy, and sustained blood-pressure lowering," she wrote. "Although zilebesiran offers new possibilities as an antihypertensive agent, it may also have therapeutic benefit in other conditions associated with activation of the renin-angiotensin system, such as kidney and heart disease."

Disclosure: This research was supported by Alnylam Pharmaceuticals. Please see the original reference for a full list of disclosures.

This article originally appeared on Renal and Urology News

Diabetes-Hypertension Care Project Launched In RHCs

LAHORE: Launching the Expanded Integrated Diabetes-Hypertension Care Project including Foot-care in 171 Rural Health Centers (RHCs) situated in 20 districts of Punjab on Thursday, the caretaker Punjab Minister for Primary and Secondary Healthcare, Dr Jamal Nasir said that diabetes and blood pressure could be prevented by adopting a healthy lifestyle.

The programme is being implemented by National Communicable Diseases Control Programme and Primary and Secondary Healthcare department in collaboration with Association for Social Development (ASD).

The project is being executed in districts Jhelum, Khushab, Sargodha, Sheikhupura, Nankana Sahib, Jhang, Khanewal, Muzaffargarh, Layyah, Okara, Attock, Rawalpindi, Sialkot, Gujranwala, Narowal, Multan, Bahawalnagar, Bahawalpur, Chiniot and Mandi Bahauddin.

Giving details of the project, the minister stated that this foot-care and suitable footwear intervention will help preventing foot complications to happen besides better managing any severe foot condition if happens in diabetes patients. He revealed that 20 district headquarters hospitals in the province will also be enabled for secondary level diabetes foot-care under this programme.

Dr Jamal Nasir advised the diabetic patients to take as much care of their feet as do they care for their face. He added that necessary consultation along with medical facilities will be provided to the diabetes patients for foot-care at these RHCs besides arrangements for access to appropriate footwear centers.

Director General Health Services, Punjab, Dr Ilyas Gondal, Dr Shaheer Elahi, Health Services Academy Islamabad, Dr Muhammad Aamir Khan Chief Coordinating Professional Association for Social Development, Dr Umar Awan and others attended the ceremony.

Copyright Business Recorder, 2023

---